Sepiapterin
Phase 3RecruitingInterest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Phenylketonuria
Conditions
Phenylketonuria
Trial Timeline
Mar 4, 2024 → Feb 28, 2031
NCT ID
NCT06302348About Sepiapterin
Sepiapterin is a phase 3 stage product being developed by PTC Therapeutics for Phenylketonuria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06302348. Target conditions include Phenylketonuria.
What happened to similar drugs?
7 of 20 similar drugs in Phenylketonuria were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06302348 | Phase 3 | Recruiting |
Competing Products
20 competing products in Phenylketonuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SYNB1934v1 + Placebo | Synlogic | Phase 3 | 22 |
| SYNB1618 + Placebo | Synlogic | Phase 1/2 | 22 |
| SYNB1618 + SYNB1934 | Synlogic | Phase 2 | 25 |
| Kuvan® | Merck | Phase 3 | 40 |
| Kuvan® | Merck | Approved | 43 |
| SAR444836 | Sanofi | Phase 1/2 | 36 |
| Kuvan | BioMarin Pharmaceutical | Pre-clinical | 15 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 32 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 32 |
| Sapropterin (Kuvan) | BioMarin Pharmaceutical | Pre-clinical | 23 |
| BMN 165 (rAvPAL-PEG) | BioMarin Pharmaceutical | Phase 2 | 32 |
| BMN 307 | BioMarin Pharmaceutical | Phase 1/2 | 33 |
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 23 |
| Sapropterin dihydrochloride + Placebo | BioMarin Pharmaceutical | Phase 3 | 37 |
| BMN165 20mg/day + BMN165 40mg/day + Placebo | BioMarin Pharmaceutical | Phase 3 | 37 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 3 | 37 |
| saproterin dihydrochloride | BioMarin Pharmaceutical | Approved | 40 |
| sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo | BioMarin Pharmaceutical | Phase 1 | 26 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 30 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 23 |